We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Medgenics(Regs) | MEDG | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 302.50 | 01:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 302.50 |
| Top Posts |
|---|
Posted at 27/6/2011 09:30 by aim_trader Medgenics CEO Andy Pearlman says there's enormous opportunity with its Biopump technologyMonday, June 27, 2011 Dr Andy Pearlman, CEO at Medgenics, tells Proactive Investors that the company's patent, the Biopump, is an inexpensive, efficient and reliable method in treating chronic diseases. He says that with the $130bln market last year for the sale of proteins, the Biopump has the potential to be able to cut this cost considerably. Andy hopes to cut another deal that will enable Medgenics to continue without having to go back to the markets. |
Posted at 20/11/2010 06:15 by jammytass sicilian_kan thanks> are we the only investors in this? |
Posted at 08/11/2010 08:04 by sicilian_kan From the FDA filing, it is intended that the US issued shares are issued at a substantially higher price than the current AIM share price. This an excellent deal for current shareholders:"The estimated initial public offering price of $ per share of common stock is substantially higher than the pro forma net tangible book value per share of our outstanding shares immediately after the offering. As a result, investors purchasing shares in the offering will incur immediate and substantial dilution of approximately $ per share or approximately % of the assumed offering price. Accordingly, existing shareholders will benefit disproportionately from this offering. If we raise additional capital through the sale of equity, including convertible securities, your percentage of ownership will be diluted. You may also experience additional dilution if stock options or warrants to purchase our shares are exercised at less than the offering price. As of the date of this prospectus, we have reserved 60,500,000 shares of our common stock for issuance under our 2006 Stock Incentive Plan, as amended (the 2006 Stock Plan), shares of our common stock for issuance upon exercise of the warrants issued in our private placements and to consultants and shares of our common stock for issuance upon the exercise of warrants to be issued to the underwriters at the completion of this offering". |
Posted at 25/8/2010 14:23 by jammytass thanks sicillian> you would think if the cmpy want pi investors they would make sure there where normal dealing in place tel dealings costs shed loads more then online and it might just put pi off the cmpy ie your £750 buy tel would cost aprox £34.00 not cheep |
Posted at 24/8/2010 07:42 by sicilian_kan Top news below. The $1-3m fundraising will be done at 13p conversion rate, just 4% interest and will be non-dilutive if repaid! And what a great result to do it at the higher MEDU price. They could easily have done it at the MEDG price. Now, what will happen to MEDG! No investor in Medgenics will invest in something with a 13p conversion rate and a one year term if collecting the interest when they can buy at 8p and convert in one year to the higher MEDU. It wouldn't surprise me at all to see the MEDG price rise to 13p in the coming days. Note, the Company expects the fundraising to close during the first two weeks of September (that is an ambitious and confident approach - suggests they are already nearly / there) and will make a further announcement upon such closing. Oh yes, and why have the automatic conversion rate of 16p for a US listing?? Are they planning one? Sounds like it is being hinted at. A US listing for this stock would be great. NASDAQ etc. know how to properly value bios and the m/cap should soar on such an event. Medgenics, Inc. ("Medgenics" or the "Company") Proposed New Convertible Debenture Issue Misgav, Israel and London, UK - 24 August 2010 - Medgenics (AIM: MEDG and MEDU), the company that has developed a novel technology for the manufacture and delivery of therapeutic proteins continuously in patients using their own tissue, is seeking to raise additional funds to finance further advances with its Phase I/II clinical trial for its product EPODURE (for the treatment of anaemia) and to initiate steps towards the launch of a Phase I/II trial for its product INFRADURE (for the treatment of hepatitis-C), through the sale of $1-3 million of new convertible debentures. The new convertible debentures will be unsecured obligations of the Company, will accrue interest at 4% per annum and will mature and become repayable 12 months from the date of issuance. Holders of such debentures may convert them anytime into shares of common stock, $0.0001 par value per share ("Common Stock"), at a conversion price of 13p. The debentures will automatically convert upon an underwritten public offering of Common Stock raising at least $6 million and resulting in the Common Stock being listed on a U.S. national securities exchange or automated quotation system (a "US Listing"), at a conversion price equal to the lesser of 13p and 75% of the public offering price of the Common Stock in such underwritten public offering. Purchasers of these new convertible debentures will receive warrants to purchase a number of shares of Common Stock equal to 75% of the number of shares of Common Stock into which the debentures convert. Such warrants will be immediately exercisable, have a 5 year term and have an exercise price of 16p. If a further issuance of securities is made by the Company at a lower price, both the conversion price of the debentures and the exercise price of the warrants will be subject to downward adjustment to such lower issue price and, if such issuance takes place prior to a US Listing occurring, the number of warrants held by each warrantholder will be increased to maintain the aggregate exercise price of his original warrants. Any Common Stock issued upon conversion of the debentures and exercise of the warrants will be deemed restricted stock under U.S. securities laws and cannot be sold or transferred unless subsequently registered under such laws or an exemption from the registration requirements is available. No application will be made for the debentures or the warrants to be admitted to trading on the AIM market of the London Stock Exchange or any other stock exchange. This new series of convertible debentures will be offered and sold in a private placement transaction only (i) in the USA to "accredited investors" as such term is defined in Regulation D promulgated under the United States Securities Act of 1933, as amended, who have already been contacted by the Company and (ii) in the UK to investment professionals and other persons to whom such an offer may lawfully be made under the Financial Services and Markets Act 2000 and associated regulations. The Company expects the fundraising to close during the first two weeks of September and will make a further announcement upon such closing. This announcement is being made for regulatory purposes and no offer or sale of securities is being made by, or should be construed as a result of, this announcement. |
Posted at 05/7/2010 08:22 by sicilian_kan Statement re: Share Price DiscrepancyTIDMMEDG Medgenics Inc 05 July 2010 ? Medgenics, Inc. ('Medgenics' or the 'Company') Statement Regarding Share Price Discrepancy Medgenics (AIM: MEDG and MEDU), the company that has developed a novel technology for the manufacture and delivery of therapeutic proteins continuously in patients using their own tissue, has noted the widening discrepancy between the mid-market price of the MEDU and MEDG quotes for common shares of par value US $0.0001 each in the Company ("Common Shares"). The Company would like to confirm that all of its issued and outstanding Common Shares, whether trading on the MEDU line or the MEDG line, rank pari passu in all respects and carry equal voting rights and equal rights to dividends. The only difference between the two quotes (MEDU and MEDG) is that the Common Shares trading on the MEDG line were when issued and remain subject to restrictions on transfer under the US Securities Act of 1933 (as amended) (the "US Securities Act"). The MEDG line of Common Shares cannot be settled electronically in the CREST system and, instead, settle in CREST only on a cash basis, with the buyer being responsible for re-registering the certificated holding. Buyers and sellers of the MEDG line of stock are both required to complete a representation letter in connection with a dealing in Common Shares trading on the MEDG line in order to assure compliance with the transfer restrictions and for settlement to be facilitated. A significant number of the Common Shares trading on the MEDG line may now qualify to have the restrictions lifted and for migration to the MEDU line of Common Shares. Other than the transfer restrictions, the Company confirms that there are no differences in rights between the Common Shares quoted on the MEDU line and those quoted on the MEDG line. For further information regarding the applicable restrictions on transfer on MEDG quoted Common Shares, the ability to transfer Common Shares from the MEDG line onto the MEDU line, participation in the depository interest arrangements that have been established by the Company and the transfer of Common Shares within CREST, shareholders should refer to the announcement made by the Company on 12 November 2008 or contact the Company directly at investor-relations@m |
Posted at 23/6/2010 07:48 by sicilian_kan RNS Number : 9877N Medgenics Inc 22 June 2010Medgenics, Inc. ('Medgenics' or the 'Company') Higher Dose EPO Biopumps Working in Patients Misgav, Israel and London, UK -22 June 2010 - Medgenics, Inc. (AIM: MEDG, MEDU), the company that has developed a novel technology for the manufacture and delivery of therapeutic proteins continuously in patients using their own tissue, is pleased to announce that the first new patients have now successfully commenced their treatment using biopumps producing middle dose levels of EPO in the Company's ongoing Phase I/II clinical trials with EPODURE. The new patients were also the first to have their Biopumps prepared at a remote site (the GMP processing center in Jerusalem), transported in a sealed chamber and subsequently administered locally at a major teaching hospital in Tel Aviv - thus successfully demonstrating the concept of a regional Biopump processing center serving a local treatment center, which is important for the wider implementation planned in the future. In the first part of the Company's Phase I/II clinical trial, completed in 2009 at the Hadassah Medical Center in Jerusalem, the equivalent of the lowest recommended dose for EPO (20 IU/kg/day) was prepared at the local GMP center and administered in 6 of the patients treated and one patient was treated with the middle recommended dose (40 IU/kg/day). The biopumps produced EPO continuously in all the patients, elevating or maintaining the haemoglobin levels in many, even with the lowest EPO dose, with most continuing for the 6 month duration of the trial and one for more than 20 months. This second part of the trial is being conducted at the Tel Aviv Medical Center, and is aimed at treating new patients with the medium and higher continuous doses to confirm that haemoglobin will be maintained or elevated over the period of the trial at higher dosage levels of EPO delivery. Demonstrating elevation of the haemoglobin level and its maintenance within the normal therapeutic range are primary objectives of this trial. In this new stage of the continuing Phase I/II clinical trial, sufficient EPODURE biopumps will be administered to each patient to provide 40 IU/kg/day. Two weeks ago, the team conducting the trial at Tel Aviv Medical Center successfully harvested micro-organs from the first two new patients entering the study and processed them to become EPODURE biopumps. These biopumps produced sufficient EPO per day that only 3 or 4 biopumps were necessary in each patient, and these were administered to them on June 17. The treatment of these new patients is possible as a result of the recently announced, successful fundraising rounds. The Company is now delivering on its plan to move forward with these trials, which have already demonstrated safety and proof of concept of the EPODURE biopump, and now aim to show a trend of greater haemoglobin responses with the higher doses administered. Following the implantation, the EPO measurements from the post-implant blood samples have confirmed a significant rise in serum EPO levels, demonstrating that the biopumps are efficiently delivering the protein in these patients. In the previous part of this trial, confirmed EPO production in situ was followed by an elevation of haemoglobin levels within the ensuing months and the Company is confident that this will also happen in this higher dose stage of the trial. Dr. Andrew Pearlman, CEO of Medgenics commented: "We are very pleased that the first patients in the new part of our study have now commenced their treatment. We are particularly impressed with the potency of the EPODURE biopumps from these patients, which has enabled them to receive the medium dose using only a few biopump units, and with their successful preparation at a remote site Biopump processing center, establishing a model for wider future implementation. We now look forward to monitoring the haemoglobin response in these patients, while recruiting additional patients to the trial in the coming months. We are optimistic that this higher dose will confirm that the middle dose biopumps work well and that the therapeutic response is dose dependent and without adverse effects. As this is an open trial, we look forward to keeping investors updated as we treat additional patients and review the ongoing trial data." |
Posted at 17/5/2010 08:23 by sicilian_kan This is surely a sign of progress. From SVS Securities to Nomura:For release: 17 May 2010 Medgenics, Inc. ("Medgenics" or the "Company") Appointment of Nomura-Code as Joint-Broker Medgenics (LSE: MEDG, MEDU), the company that is developing a novel approach to the manufacture and delivery of therapeutic proteins continuously in patients using their own tissue, is proud to announce today the appointment of Nomura Code Securities as joint-broker to the Company with SVS Securities plc with immediate effect. Commenting on the new appointment Dr. Andrew Pearlman, CEO of Medgenics said: "We are delighted by this new appointment and believe that the combination of Nomura Code Securities, with acknowledged expertise in the life sciences space and its reputation amongst institutional investors, and SVS Securities plc, with its small cap investor expertise, greatly strengthens Medgenics broking team to support the Company going forward" |
Posted at 25/4/2010 18:24 by sicilian_kan Mention on Red Hot Penny Shares today:"The biotech and pharmaceutical "strongholds" that could see you make huge profits... whatever the economy does next. In 2010, the biotech and pharmaceutical sector will be the savvy investors' niche. Recession has hit other industries where it hurts...but disease and illness aren't governed by the same rules as the economy... The human race seems to be contracting more viruses, infections and diseases than ever before...and it's the tiny small cap biotechnology and pharmaceutical companies - not the industry's heavyweights, like AstraZeneca and GlaxoSmithKline - that are delivering the answers. The investor that knows where to look - and when to invest - could make serious, serious money from under-valued biotech and pharma penny shares over the next year. How one breakthrough could see you pocket fast triple figure gains... Just check out these biotech and pharma success stories from the 3 months between August and October: * Phytopharm (ticker: PYM) shot up a staggering 278%... after news of their new Parkinson's drug was released * Medgenics (ticker: MEDG) shares soared by 78%... when they signed a new deal for their revolutionary product to treat haemophilia * Verona Pharma (ticker: VRP) rocketed by 117 %... thanks to positive trials of their asthma drug RPL554 ..." |
Posted at 27/8/2009 10:25 by simonparker5 LOOKS VERY INTERESTING!TIDMMEDG RNS Number : 1018Y Medgenics Inc 27 August 2009 Medgenics, Inc. ('Medgenics' or the 'Company') PATIENT NEARING UNPRECEDENTED 11 MONTHS OF ANEMIA RELIEF IN CLINICAL TRIAL FROM SINGLE TREATMENT OF BIOPUMP TISSUE TECHNOLOGY NEWS FOLLOWS SIGNIFICANT INTEREST OF STRATEGIC PARTNER FOR NEW APPLICATION * EPODURE patient approaching 11 months continuous anemia relief from single treatment, and reaching one year anniversary without any injections of EPO; * Significant new interest from major pharmaceutical companies to develop a Biopump for new applications; * Serious new interest from institutional investors; and * Medgenics awarded $1.3 million Israeli government grant. August 27, 2009 - Medgenics (AIM:MEDG, MEDU) is pleased to announce that one of the patients, who was treated with the Company's EPODURE tissue Biopumps almost 11 months ago, continues to be effectively treated for anemia without a single erythropoietin (EPO) injection. This patient (#2) was dependent on frequent injections of the therapeutic protein (EPO) for the 18 months prior to receiving a single administration of 3 tiny EPODURE tissue Biopumps in the Company's phase I/II anemia trial in Israel. He has now gone a full year since his last EPO injection, while his hemoglobin level has been continuously maintained within the target range of 10-12 g/dl for this period. By contrast, conventional anemia treatment by EPO injections must be repeated up to 3 times every week to provide sustained treatment. To the best of the Directors' knowledge, nothing approaching EPODURE'S length of sustained anemia relief in patients has been shown from a single treatment of any other kind. The patient (#2), stated: "For me the treatment has been and continues to be successful, without complications or discomfort. At 72 years old, I continue to do physical work in the citrus groves several hours a day, but unlike in the previous year, I have not needed injections. The treatment has improved my quality of life." Medgenics' unique tissue-based EPODURE Biopump platform technology is proving to be effective in maintaining hemoglobin levels within the target range for many months in most of the patients treated so far, even at lowest dose of treatment, according to internationally renowned nephrologist, Dr. Anatole Besarab, who is a member of Medgenics' Scientific Advisory Board.The Company plans to present the study findings at the upcoming American Society of Nephrology meeting in October. Dr. Besarab has said: "With a patient now nearing 12 months without EPO injections and others for more than 6 months, it is becoming clearer that the EPODURE Biopump is able to produce sufficient erythropoietin to effectively elevate and then sustain hemoglobin levels in patients with sufficient administered dose.I am not aware of any other technology that can achieve such prolonged and sustained therapy from a single treatment. Additional studies are needed in a broader range of patients, and we look forward to them to further confirm these very positive results." Medgenics has also recently moved significantly ahead in discussions with major pharmaceutical companies and with institutional investment funds. Advanced discussions are now underway towards potential partnership in the coming months to co-develop a Biopump producing Factor VIII protein for the treatment of hemophilia, a market greater than $3.5b/year (La Marie 2007). In addition, the Company has recently entered advanced discussions with institutional investors interested in multimillion dollar investment in Medgenics in the coming months. Medgenics is also in active due diligence with an Asian biopharma company that has conveyed its written interest in a combined investment in the Company and licensing agreement for collaboration in certain Biopump applications in selected Asian markets to be agreed. The Board is also pleased by recent serious interest by companies in other new applications of the Biopump platform, and believes that such interest demonstrates the attractiveness of the Biopump platform for strategic partners. The Directors believe that these discussions could lead to concrete steps in the coming months. In addition to the closing and commitment of additional funds announced last week, which brought the total to $520,000, Medgenics notes that it was awarded a government grant in Q2/09 of $1.3 million from the Office of the Chief Scientist (OCS) at the Ministry of Industry, Trade and Labor of Israel. These funds will be received as government participation in approved R & D expenses incurred during the period April 2009 to March 2010. The OCS awards grants to industry in Israel to advance technological innovations. This is the fourth consecutive year that Medgenics has received this respected grant. Dr. Andrew Pearlman, CEO of Medgenics said "We are excited that we have a patient who is now reaching a full year of effective anemia treatment without any EPO injections and with only a single treatment of EPODURE. In this period a typical patient in the U.S. being treated per the FDA guidelines for EPO administration would receive up to 150 injections. Month by month we have drawn growing encouragement from the continuing positive results of the Biopump anemia study. We are pleased by the significant progress with potential partners and institutional investors which gives us great hope that this will yield concrete results in the coming months. Meanwhile, the Company continues its focused efforts to raise several million US$ in the coming months to enable it to continue and expand the clinical trial and our other operations and to realize the potential of the great opportunities it now has." The Company would also like to clarify that, further to the announcement made on 20 August 2009, included within the $55,000 debenture investment by "shareholders who are physicians with expertise in the clinical field addressed by Medgenics' lead product, EPODURE" was an investment of US $5,000 from Stephen McMurray, a director of the Company. For further information, contact: Medgenics, Inc.+972 4 902 8900 Dr. Andrew L. Pearlman |
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
